Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten, Xenofon Baraliakos, J. Braun, et al.
The Lancet (2013) Vol. 382, Iss. 9906, pp. 1705-1713
Closed Access | Times Cited: 568

Showing 1-25 of 568 citing articles:

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten, Joachim Sieper, J. Braun, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 26, pp. 2534-2548
Open Access | Times Cited: 903
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
Laure Gossec, Josef S Smolen, Sofía Ramiro, et al.
Annals of the Rheumatic Diseases (2015) Vol. 75, Iss. 3, pp. 499-510
Open Access | Times Cited: 885
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates, Arthur Kavanaugh, Philip J. Mease, et al.
Arthritis & Rheumatology (2016) Vol. 68, Iss. 5, pp. 1060-1071
Open Access | Times Cited: 880
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Michele W.L. Teng, Edward P. Bowman, Joshua McElwee, et al.
Nature Medicine (2015) Vol. 21, Iss. 7, pp. 719-729
Closed Access | Times Cited: 779
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease, Iain B. McInnes, Bruce Kirkham, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 14, pp. 1329-1339
Open Access | Times Cited: 683
Osteoimmunology: evolving concepts in bone–immune interactions in health and disease
Masayuki Tsukasaki, Hiroshi Takayanagi
Nature reviews. Immunology (2019) Vol. 19, Iss. 10, pp. 626-642
Closed Access | Times Cited: 552
IL-17 and IL-17-producing cells in protection versus pathology
Kingston H. G. Mills
Nature reviews. Immunology (2022) Vol. 23, Iss. 1, pp. 38-54
Open Access | Times Cited: 523
Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems
Kazuo Okamoto, Tomoki Nakashima, Masahiro Shinohara, et al.
Physiological Reviews (2017) Vol. 97, Iss. 4, pp. 1295-1349
Open Access | Times Cited: 439
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Josef S Smolen, Daniel Aletaha
Nature Reviews Rheumatology (2015) Vol. 11, Iss. 5, pp. 276-289
Closed Access | Times Cited: 432
Mechanisms of human autoimmunity
Michael D. Rosenblum, Kelly A. Remedios, Abul K. Abbas
Journal of Clinical Investigation (2015) Vol. 125, Iss. 6, pp. 2228-2233
Open Access | Times Cited: 421
Management of psoriasis as a systemic disease: what is the evidence?
Neil J. Korman
British Journal of Dermatology (2019) Vol. 182, Iss. 4, pp. 840-848
Open Access | Times Cited: 387
Basic biology and role of interleukin‐17 in immunity and inflammation
Camille Zenobia, George Hajishengallis
Periodontology 2000 (2015) Vol. 69, Iss. 1, pp. 142-159
Open Access | Times Cited: 381
IL-17 in Chronic Inflammation: From Discovery to Targeting
Audrey Beringer, Mélissa Noack, Pierre Miossec
Trends in Molecular Medicine (2016) Vol. 22, Iss. 3, pp. 230-241
Closed Access | Times Cited: 376
Robust meta‐analytic‐predictive priors in clinical trials with historical control information
Heinz Schmidli, Sandro Gsteiger, Satrajit Roychoudhury, et al.
Biometrics (2014) Vol. 70, Iss. 4, pp. 1023-1032
Closed Access | Times Cited: 373
IL-17 in Severe Asthma. Where Do We Stand?
Julie Chesné, Faouzi Braza, Guillaume Mahay, et al.
American Journal of Respiratory and Critical Care Medicine (2014) Vol. 190, Iss. 10, pp. 1094-1101
Closed Access | Times Cited: 330
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei, et al.
Annals of the Rheumatic Diseases (2018) Vol. 77, Iss. 9, pp. 1295-1302
Open Access | Times Cited: 324
IL-17-producing γδ T cells enhance bone regeneration
T. Ono, Kazuo Okamoto, Tomoki Nakashima, et al.
Nature Communications (2016) Vol. 7, Iss. 1
Open Access | Times Cited: 311
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Stefan Siebert, Alexander Tsoukas, Jamie Robertson, et al.
Pharmacological Reviews (2015) Vol. 67, Iss. 2, pp. 280-309
Open Access | Times Cited: 296
Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar, Lianne S. Gensler, Joachim Sieper, et al.
Arthritis & Rheumatology (2018) Vol. 71, Iss. 2, pp. 258-270
Open Access | Times Cited: 283
Pathogenesis of ankylosing spondylitis — recent advances and future directions
Vidya Ranganathan, Eric Gracey, Matthew A. Brown, et al.
Nature Reviews Rheumatology (2017) Vol. 13, Iss. 6, pp. 359-367
Closed Access | Times Cited: 265
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Atul Deodhar, P. J. Mease, Iain B. McInnes, et al.
Arthritis Research & Therapy (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 258
Genetics of ankylosing spondylitis—insights into pathogenesis
Matthew A. Brown, Tony Kenna, B P Wordsworth
Nature Reviews Rheumatology (2015) Vol. 12, Iss. 2, pp. 81-91
Closed Access | Times Cited: 252
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
Denis Poddubnyy, Kay‐Geert Hermann, Johanna Callhoff, et al.
Annals of the Rheumatic Diseases (2014) Vol. 73, Iss. 5, pp. 817-823
Closed Access | Times Cited: 250
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Claudia Schinocca, Chiara Rizzo, Serena Fasano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 241
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Ariane Hammitzsch, C. Tallant, O. Fedorov, et al.
Proceedings of the National Academy of Sciences (2015) Vol. 112, Iss. 34, pp. 10768-10773
Open Access | Times Cited: 232
Page 1 - Next Page

Scroll to top